FDAapproval72% confidence
Oncology (Cancer)/Hematologic Malignancies Approval Notifications
Source: FDA
Why This Matters
Why this matters: illustrates how regulators handled a comparable approval decision relevant to Regeneron.
Regulatory Analysis
FDA does not issue approval announcements for every approval or drug label update that occurs in oncology and hematology. Please refer to Drugs@FDA for the latest approvals and prescribing information for specific products.
Supporting Context
- Therapeutic area
- Oncology · Skin Cancer
- Sub-indication
- General
Related signal: Phase III Trial Evaluates Cemiplimab with Surgery for Advanced Skin Cancer
Source
FDA document
View source